- Home
- EVAX vs SABS Comparison
EVAX vs SABS Comparison
Compare EVAX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- SABS
- Stock Information
- Founded
- EVAX 2008
- SABS 2014
- Country
- EVAX Denmark
- SABS United States
- Employees
- EVAX N/A
- SABS N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- SABS Health Care
- Exchange
- EVAX Nasdaq
- SABS Nasdaq
- Market Cap
- EVAX 15.1M
- SABS 15.8M
- IPO Year
- EVAX 2021
- SABS N/A
- Fundamental
- Price
- EVAX $2.61
- SABS $2.23
- Analyst Decision
- EVAX Strong Buy
- SABS Strong Buy
- Analyst Count
- EVAX 2
- SABS 5
- Target Price
- EVAX $10.00
- SABS $11.60
- AVG Volume (30 Days)
- EVAX 121.3K
- SABS 4.3M
- Earning Date
- EVAX 08-13-2025
- SABS 08-12-2025
- Dividend Yield
- EVAX N/A
- SABS N/A
- EPS Growth
- EVAX N/A
- SABS N/A
- EPS
- EVAX N/A
- SABS N/A
- Revenue
- EVAX $3,293,000.00
- SABS $377,835.00
- Revenue This Year
- EVAX N/A
- SABS N/A
- Revenue Next Year
- EVAX N/A
- SABS N/A
- P/E Ratio
- EVAX N/A
- SABS N/A
- Revenue Growth
- EVAX 2555.64
- SABS N/A
- 52 Week Low
- EVAX $1.20
- SABS $1.00
- 52 Week High
- EVAX $17.75
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- EVAX 49.56
- SABS 48.41
- Support Level
- EVAX $2.56
- SABS $2.25
- Resistance Level
- EVAX $3.03
- SABS $2.85
- Average True Range (ATR)
- EVAX 0.20
- SABS 0.61
- MACD
- EVAX -0.01
- SABS -0.08
- Stochastic Oscillator
- EVAX 25.00
- SABS 8.00
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.